Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Louis Weimer

Neurology New York, NY Medical Doctor

NPI 1356357404 CMS profile 15836

710 W 168Th St, New York, NY 10032

Open in the dashboard

General payments

$91,548

141 records reported · program years 2019–2025

Research payments

$1,104

Paid to them · 8 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Louis Weimer of New York, NY is reported in the CMS Open Payments database as having received $91,548 across 141 general payments and $1,104 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,717 19
2025 Research $1,104 8
2024 General $6,677 20
2023 General $8,647 16
2022 General $9,395 7
2021 General $4,802 6
2020 General $26,714 20
2019 General $26,598 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Louis Weimer
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Louis Weimer were reported at $8,717. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Louis Weimer Neurology median Middle half National median
2019 $26,598 $474 $118–$2,177 $163
2020 $26,714 $367 $82–$2,309 $114
2021 $4,802 $438 $104–$2,547 $132
2022 $9,395 $442 $103–$2,388 $149
2023 $8,647 $464 $119–$2,312 $160
2024 $6,677 $468 $119–$2,323 $164
2025 $8,717 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $88,996 42 payments
  2. Alexion Pharmaceuticals, Inc. $570 21 payments
  3. Catalyst Pharmaceuticals, Inc. $311 12 payments
  4. EDW Pharma, Inc. $298 1 payment
  5. Novartis Pharmaceuticals Corporation $190 12 payments
  6. Argenx US, Inc. $155 6 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $145 6 payments
  8. CSL Behring $120 5 payments
  9. Lundbeck LLC $112 6 payments
  10. Grifols USA, LLC $105 5 payments
  11. Other $545 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $88,996 42 payments
  2. Food and Beverage $2,515 97 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $37 2 payments
Products named General payments · program years 2019–2025
  1. Non-Covered Product $41,796 19 payments
  2. Evrysdi $38,455 18 payments
  3. ULTOMIRIS $401 14 payments
  4. FIRDAPSE $311 12 payments
  5. Tiglutik $298 1 payment
  6. Soliris $168 7 payments
  7. VYVGART Hytrulo $155 6 payments
  8. Hizentra $120 5 payments
  9. NORTHERA $112 6 payments
  10. Gamunex-C $105 5 payments
  11. Other $776 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $1,104 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

460

Median for Neurology: 833

Drug cost

$1,906,500

Median for Neurology: $202,670

Branded share of claims

25.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Firdapse Amifampridine Phosphate Brand 13 $907,875
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 18 $449,923
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 39 $375,114
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 30 $89,654
Droxidopa Generic 21 $63,969
Pyridostigmine Bromide Generic 136 $11,954
Midodrine Hcl Generic 27 $5,052
Gabapentin Generic 62 $996
Sodium Chloride 0.9 % Sodium Chloride Brand 16 $595
Duloxetine Hcl Generic 28 $486

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$90,198

Medicare's payments for the services billed

Medicare patients

278

Average age 70

Services billed

904

140 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 63%
Ischemic heart disease 33%
Diabetes 28%
Depression 28%
Osteoporosis 25%
Cancer 19%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Evrysdi
  • F. Hoffmann-La Roche AG $6,278
$6,278 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $144
$144 — —
VYVGART Hytrulo
  • ARGENX US, INC. $81
$81 — —
HYQVIA
  • Takeda Pharmaceuticals U.S.A., Inc. $71
$71 — —
FIRDAPSE
  • CATALYST PHARMACEUTICALS, INC. $60
$60 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record